Share this Post!
  1. Rationale

Pursuant to Book I, Article VII, Sec. 1 of the Implementing Rules and Regulations (IRR) of the Republic Act (RA) No. 9711, otherwise known as the “Food and Drug Administration Act of 2009”, there shall be, under the Office of the Director-General, four (4) Centers covering the four (4) major product categories that are regulated under FDA. Among the four (4) Centers is the Center for Cosmetics Regulation and Research (to include household/urban hazardous substances), which shall regulate the manufacture, importation, exportation, distribution, sale, offer for sale, transfer, promotion, advertisement, sponsorship of, and/or, where appropriate, the use and testing of cosmetics and household/urban hazardous substances. The Center shall likewise conduct research on the safety and quality of cosmetics and household/urban hazardous substances, and institute standards for the same.

There is a need to rename the title of the Center for Cosmetics Regulation and Research to provide clarity on the scope of its jurisdiction, covering cosmetics and household/urban hazardous substances in accordance with the law.

  1. Declaration

Consistent with the provisions of RA 9711 and Its IRR, it is hereby declared that the Center for Cosmetics Regulation and Research shall now be referred to as the Center for Cosmetics and Household/Urban Hazardous Substances Regulation and Research.

All internal and external communications, authorizations, certifications, orders, advisories, and other legal documentations, as applicable, shall reflect the above title accordingly.

Nothing in this issuance shall authorize the creation of a new Center or Office within the Food and Drug Administration. The renaming shall only affect the title of the Center, and shall not extend to creation of new, or modification of existing organizational structure, mandate, functions, powers, and duties accorded to the Center.

This Circular shall take effect immediately following the completion of its publication in a newspaper of general circulation and submission of a copy hereof to the University of the Philippines Office of the National Registry (UP-ONAR).

Attachment:-> FDA-Circular-No.2020-032